 |
|
|
| |
Antiviral Activity, Safety and Pharmacokinetics of IDX320, a Novel Macrocyclic HCV Protease Inhibitor, in a 3-Day Proof-of-Concept Study in Patients with Chronic Hepatitis C
|
| |
| |
Reported by Jules Levin AASLD Nov 2 2010 Boston
H.W. Reesink1, J. de Bruijne1, A.A. van Vliet2, F. Muhr-Wilkenshoff 2, C. Weegink1, W. Mazur3, A. Wiercinska-Drapao4, K. Simon5, G. Cholewinska-Szymanska4, J. Kapocsi6, I. Varkonyi7, X.J. Zhou8, M.F. Temam8, J. Molles8, J. Chen8, K. Pietropaolo8, J.Z. Sullivan-Bolyai8 and D. Mayers8
1Academic Medical Center, Amsterdam, NL; 2Pharmaceutical Research Associates Group, Zuidlaren, NL and Berlin, Germany; 3Specialist Hospital, Chorzow, Poland; 4Hospital of Infectious Diseases, Warsaw, Poland; 5Provincial Specialist Hospital, Wrocaw, Poland; 6Semmelweis University, Budapest, Hungary; 7Infectious Disease Hospital, Debrecen, Hungary; 8Idenix Pharmaceuticals, Inc., Cambridge, MA, USA and Montpellier, France.
Values are reported as means±SD, except for Tmax where medians (min-max) are reported. For Ctrough, (min-max) is also shown; Ctrough is C24h for QD and C12h for BID.
# AUC is AUC0-24h for QD and AUC0-12h for BID; For BID, daily AUC0-24h (not shown) can be calculated as the sum of the AM and PM AUC.
REFERENCES
1. Lallos LB, McCarville J, Li B, et al (2010). Journal of Hepatology 52 Suppl. 1 298-99
2. van de Wetering de Rooij J, Zhou XJ, Temam MF et al (2010). 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy. June 23rd, 2010; Boston, Massachusetts.
|
| |
|
|
|
|
|
